Akero Therapeutics, Inc.
AKRO
$37.63
$0.190.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -66.09% | -98.29% | -76.75% | -60.30% | -35.46% |
| Total Depreciation and Amortization | -37.93% | -86.49% | -79.07% | -55.81% | -32.56% |
| Total Amortization of Deferred Charges | -22.68% | -27.14% | -31.48% | 162.17% | 284.80% |
| Total Other Non-Cash Items | 49.66% | 20.15% | -33.98% | -43.96% | -48.38% |
| Change in Net Operating Assets | 144.95% | 148.02% | 53.84% | 233.65% | -49.59% |
| Cash from Operations | -58.29% | -73.13% | -96.53% | -65.34% | -57.12% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 51.39% | 67.09% | -48.19% | -165.80% | -250.37% |
| Cash from Investing | 50.94% | 66.79% | -48.67% | -165.80% | -250.37% |
| Total Debt Issued | -33.33% | -33.33% | -33.33% | -60.00% | 50.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 28.78% | 1.68% | -37.34% | 167.01% | 30.27% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -8.76% | 94.25% | 94.82% | 95.00% | 94.71% |
| Cash from Financing | 26.19% | 4.17% | -35.72% | 160.52% | 38.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 776.48% | 144.49% | -150.24% | 240.67% | -115.79% |